Genprex Inc (GNPX) saw an uptrend of 30.15% in the recent trading with $0.25 being its most recent. The current price level -93.64% lower than the highest price of $3.97 marked by the stock while trading over the past 52-weeks, whereas it is 80.36% higher than the lowest price of $0.14 the company dropped to over past 52-weeks. The latest news story on GNPX appeared in (PR Newswire) under the title “Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Genprex Inc Earnings – What Happened With GNPX
Coming around sales and income figures on GNPX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Genprex Inc (GNPX) last released financial results for the quarter that ended 6/30/2024, posting a surprise factor of -30.43% for net revenue.
GNPX – Genprex Inc Stock Earnings Estimates
The perspective of Genprex Inc (NASDAQ:GNPX)’s current quarter earnings identifies that analysts are in consensus over the estimate of -2.3 for stock’s EPS in the current quarter. Genprex Inc (GNPX) last released financial results for the quarter that ended 6/30/2024, posting a surprise factor of -30.43% for net revenue. Company’s EPS for the last quarter was -3.
Genprex Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 42.91 million. GNPX does have institutional investors; and they hold 1.83% of the stock.
As on 2024-06-30, ARMISTICE CAPITAL, LLC was the top most holder in Genprex Inc (NASDAQ:GNPX) with an ownership of 0.22 million shares of the company or 10.0834 of the stake worth $0.41 million. The filing also reveals GEODE CAPITAL MANAGEMENT, LLC as the second largest holder in the company with a control over 0.7631 of the outstanding shares. Its stake is worth $31103.0 for having 16497.0 shares in hand.
VANGUARD GROUP INC also came holding a key position in the company during the recent quarter and it now holds 0.7084 of the outstanding shares. With this there are now 32.0 institutions which have possession in GNPX’s shares.
Key Metrics for GNPX
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Genprex Inc has a debt to equity ratio of 0.00.
